Last reviewed · How we verify

NCT06690567: IMMERGE

Clinical Outcomes of Contemporary IMPELLA Devices in Cardiogenic Shock and High-risk Percutaneous Coronary Intervention

Status unknown Last updated 15 November 2024
What this trial tests

trial testing Impella implantation in Cardiogenic Shock in 700 participants. Status unknown.

Timeline
10 October 2024
Primary endpoint
10 December 2024
10 December 2024

Quick facts

Lead sponsorA.O.U. Città della Salute e della Scienza
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment700
Start date10 October 2024
Primary completion10 December 2024
Estimated completion10 December 2024
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

A.O.U. Città della Salute e della Scienza — full company profile →

Who can join

18 and older, any sex, with Cardiogenic Shock or PCI Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The IMMERGE registry is an observational, international multicentric study, including patients underwent IMPELLA implantation in the participating centers both for cardiogenic shock and high-risk PCI. Only IMPELLA CP, 5.0 and 5.5 devices will be included. Consecutive patients with CS and CHIPs implanted with Impella® CP, 5.0 and 5.5 with at least 6 months of follow-up completed will be enrolled in the registry. Baseline clinical and echocardiographic variables, peri-procedural haemodynamic parameters, laboratoristic findings and complications, together with follow-up outcomes data will be recorded in a dedicated database.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiogenic Shock

Currently open trials in the same condition.

Other A.O.U. Città della Salute e della Scienza trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06690567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing